SCHEMBL16570153

SCHEMBL16570153

CN(c1ccccc1Cn1ccc2cnc(Nc3ccc(-n4ccccc4=O)cc3)nc21)S(C)(=O)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT6 P42226 2/20 0.48
▸ PTK2 Q05397 13/20 0.47
▸ JAK2 O60674 11/20 0.47
▸ JAK3 P52333 8/20 0.46
▸ PTK2B Q14289 1/20 0.46
▸ CDK4 P11802 3/20 0.43
▸ CCND1 P24385 2/20 0.43
▸ CCND2 P30279 2/20 0.43
▸ CCND3 P30281 2/20 0.43
▸ AURKA O14965 2/20 0.42
▸ DCLK1 O15075 1/20 0.42
▸ PDPK1 O15530 1/20 0.42
▸ ROCK2 O75116 1/20 0.42
▸ PRKD3 O94806 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ EGFR P00533 1/20 0.42
▸ NTRK1 P04629 1/20 0.42
▸ PRKCG P05129 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ FYN P06241 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16570475 0.89 SRPK2 (0.49) STAT6PTK2JAK2JAK3PTK2B
SCHEMBL16581005 0.88 PTK2 (0.51) STAT6PTK2JAK2JAK3PTK2B
SCHEMBL16570232 0.87 PTK2 (0.50) STAT6PTK2JAK2JAK3PTK2B
SCHEMBL16570687 0.85 STAT6 (0.69) STAT6PTK2JAK2JAK3CDK4
SCHEMBL16570299 0.85 JAK2 (0.64) STAT6PTK2JAK2JAK3CDK4
SCHEMBL16580780 0.84 PTK2 (0.48) STAT6PTK2JAK2JAK3PTK2B
SCHEMBL16580795 0.84 STAT6 (0.56) STAT6PTK2JAK2JAK3CDK4
SCHEMBL16570177 0.84 STAT6 (0.58) STAT6PTK2JAK2JAK3CDK4
SCHEMBL16570119 0.84 STAT6 (0.56) STAT6PTK2JAK2JAK3CDK4
SCHEMBL16571033 0.84 STAT6 (0.52) STAT6PTK2JAK2JAK3PTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN STAT6 103/4885PTK2 2/4885JAK2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback